Citigroup Inc Anavex Life Sciences Corp. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Citigroup Inc holds 571,645 shares of AVXL stock, worth $2.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

571,645

Previous 102,688 456.68%

Holding current value

$2.36 Million

Previous $956,000 204.29%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$4.55 - $6.75 $2.13 Million - $3.17 Million	468,957 Added 456.68%	571,645 $2.91 Million
Q4 2023 Feb 09, 2024	SELL	$5.04 - $9.95 $79,420 - $156,792	-15,758 Reduced 13.3%	102,688 $956,000
Q3 2023 Nov 09, 2023	SELL	$6.55 - $9.37 $36,771 - $52,603	-5,614 Reduced 4.53%	118,446 $775,000
Q2 2023 Aug 10, 2023	SELL	$7.66 - $9.5 $1.94 Million - $2.41 Million	-253,864 Reduced 67.17%	124,060 $1.01 Million
Q1 2023 May 11, 2023	BUY	$8.32 - $11.75 $1.39 Million - $1.96 Million	166,608 Added 78.84%	377,924 $3.24 Million

Q4 2022 Feb 09, 2023	SELL	$7.65 - $14.43 $362,097 - $683,015	-47,333 Reduced 18.3%	211,316 $1.96 Million
Q3 2022 Nov 10, 2022	BUY	$8.9 - $12.86 $678,055 - $979,751	76,186 Added 41.75%	258,649 $2.67 Million
Q2 2022 Aug 10, 2022	BUY	$7.31 - $12.84 $781,197 - $1.37 Million	106,867 Added 141.37%	182,463 $1.83 Million
Q1 2022 May 12, 2022	SELL	$9.74 - $17.69 $1.38 Million - $2.5 Million	-141,353 Reduced 65.15%	75,596 $931,000
Q4 2021 Feb 10, 2022	BUY	$16.88 - $23.31 $998,046 - $1.38 Million	59,126 Added 37.46%	216,949 $3.76 Million
Q3 2021 Nov 10, 2021	BUY	$16.82 - $25.75 $2.65 Million - $4.06 Million	157,823 New	157,823 $2.83 Million

Others Institutions Holding AVXL

# of Institutions

159

Shares Held

31.6M

Call Options Held

910K

Put Options Held

1.35M

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $322M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account